-transparent.png){kind=logo}
An 86-year-old man experienced a rash approximately 2 weeks after starting ticlopidine therapy, necessitating discontinuation of the drug. About 1 month later, despite discontinuation, he developed jaundice and liver test abnormalities. These resolved gradually over the next few months. Based on case reports and the drug's pharmacokinetic profile, a high index of suspicion for ticlopidine-induced jaundice is prudent in patients with recent exposure to the agent who have evidence of liver damage.
Related Publications
C J Kubin, and
O Sherman, and
K B Hussain, and
L Feinman
July 1991,
La Clinica terapeutica,
C J Kubin, and
O Sherman, and
K B Hussain, and
L Feinman
June 1993,
Clinical pharmacy,
C J Kubin, and
O Sherman, and
K B Hussain, and
L Feinman
March 1997,
Singapore medical journal,
C J Kubin, and
O Sherman, and
K B Hussain, and
L Feinman
September 2000,
American family physician,
C J Kubin, and
O Sherman, and
K B Hussain, and
L Feinman
July 1994,
American journal of hospital pharmacy,
C J Kubin, and
O Sherman, and
K B Hussain, and
L Feinman
December 1993,
Anales de medicina interna (Madrid, Spain : 1984),
C J Kubin, and
O Sherman, and
K B Hussain, and
L Feinman
May 1995,
Revista espanola de enfermedades digestivas,
C J Kubin, and
O Sherman, and
K B Hussain, and
L Feinman
March 2003,
The Annals of pharmacotherapy,
C J Kubin, and
O Sherman, and
K B Hussain, and
L Feinman
September 2000,
Anales de medicina interna (Madrid, Spain : 1984),
C J Kubin, and
O Sherman, and
K B Hussain, and
L Feinman
January 1994,
Acta clinica Belgica,
